The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| URGN | +44.89% | -11.38% | -2.39% | +29% |
| S&P | +15.06% | +95.03% | +14.29% | +182% |
UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.
The company released positive top-line results for two studies for a bladder cancer treatment.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $24.22M | 10.8% |
| Gross Profit | $20.67M | 5.3% |
| Gross Margin | 85.34% | -4.5% |
| Market Cap | $631.67M | -8.5% |
| Market Cap / Employee | $2.69M | 0.0% |
| Employees | 235 | 16.9% |
| Net Income | -$49.94M | -49.5% |
| EBITDA | -$40.85M | -59.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $93.99M | -57.4% |
| Accounts Receivable | $19.65M | 12.8% |
| Inventory | 7.1 | -4.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $125.92M | 28.2% |
| Short Term Debt | $1.55M | 94.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -63.18% | -3.0% |
| Return On Invested Capital | -584.70% | -10.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$40.36M | -72.7% |
| Operating Free Cash Flow | -$40.22M | -72.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 17.25 | 17.61 | -53.06 | -13.59 | -10.00% |
| Price to Sales | 6.13 | 5.54 | 5.71 | 6.94 | -4.51% |
| Price to Tangible Book Value | 17.25 | 17.61 | -53.06 | -13.60 | -10.00% |
| Enterprise Value to EBITDA | -24.28 | -14.19 | -12.46 | -15.26 | -17.83% |
| Total Debt | $122.75M | $124.92M | $126.36M | $127.47M | 28.71% |
URGN earnings call for the period ending September 30, 2020.
URGN earnings call for the period ending June 30, 2020.
URGN earnings call for the period ending March 31, 2020.
URGN earnings call for the period ending December 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
